Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline: 1Q18

Approvals were down last quarter. Vertex (Cambridge, MA, USA) got a green light for its small-molecule combination to combat cystic fibrosis; Theratechnologies (Montreal, Quebec, Canada) and Sun Pharmaceuticals (Mumbai, India) received registrations for monoclonal antibodies (mAbs) to treat HIV and psoriasis, respectively. A gene therapy suffered a clinical setback in Duchenne muscular dystrophy. Decisions await several new therapeutic modalities, including short-interfering RNA (siRNA) and ASO therapies against transthyretin-related (TTR)-hereditary amyloidosis; an antibody–drug conjugate for hairy cell leukemia, a nanobody against thrombotic thrombocytopenic purpura and the first new anti-malarial in 60 years.

Historic US regulatory approvals by drug classboxed-text

Notable regulatory approvals (1Q18)boxed-text

Notable regulatory setbacks (1Q18)boxed-text

Notable clinical trial results (1Q18)boxed-text

Notable upcoming catalysts (3Q18)boxed-text

Author information



Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Drug pipeline: 1Q18. Nat Biotechnol 36, 386 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing